found benefits in people with depression. Research is based on the facial feedback hypothesis. Premature ejaculation The drug for the treatment of premature ejaculation has been under development since 7 August 2013, and is in Phase II of the FDA trials. References Further reading External links BotDB: extensive resources on BoNT structures, inhibitors, kinetics, and literature F.D.A. OKs Daxxify, an Anti-Wrinkle Drug and Botox Competitor The New York Times AbbVie brands Acetylcholine release inhibitors Bacterial toxins Biological toxin weapons Botulism EC 3.4.24 Muscle relaxants Neurotoxins Peripherally selective drugs Plastic surgery Protein domains